Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome.
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
pubmed:
30
7
2019
medline:
1
9
2020
entrez:
30
7
2019
Statut:
ppublish
Résumé
Anti-cytolethal distending toxin B (CdtB) and anti-vinculin antibodies have been proposed as biomarkers that discriminate irritable bowel syndrome (IBS) diarrhea from inflammatory bowel disease; however, it is unknown whether they can also discriminate patients with IBS and IBS subtypes and functional dyspepsia (FD) from healthy individuals in the general population. We aimed to determine whether anti-CdtB and anti-vinculin can discriminate IBS and FD from health and from organic gastrointestinal (GI) disease. Adults were enrolled from 2 Australian studies: (i) a random, population-based study (n = 331) with subjects diagnosed with IBS (n = 63) or FD (n = 61) by modified Rome III criteria or healthy control subjects (n = 246) who did not meet criteria for IBS and/or FD and (ii) an outpatient-based study with subjects diagnosed with IBS (n = 256) and/or FD (n = 55) or organic GI disease (n = 182) by an independent clinician. Serum levels of anti-CdtB/anti-vinculin antibodies were determined by enzyme-linked immunosorbent assay. There was a significantly higher mean value of anti-CdtB in FD vs healthy controls (mean = 2.46 [SD = 0.72] vs mean = 2.14 [SD = 0.77]; P = 0.005) and IBS/FD overlap vs healthy controls (mean = 2.47 [SD = 0.78] vs mean = 2.14 [SD = 0.77]; P = 0.02). There were no significant differences in anti-CdtB in IBS and FD outpatients or IBS/FD subgroups compared with patients with organic GI disease. In terms of anti-vinculin, there were no significant differences between IBS and FD and healthy controls or between IBS and FD and organic GI disease controls. We did not confirm that anti-CdtB/anti-vinculin discriminated IBS diarrhea from organic GI disease in Australian subjects. However, we did find higher anti-CdtB in FD and IBS/FD overlap vs healthy controls. Postinfectious FD may be more common than currently recognized.
Identifiants
pubmed: 31356481
doi: 10.14309/ctg.0000000000000064
pmc: PMC6708662
doi:
Substances chimiques
Antibodies
0
Bacterial Toxins
0
Biomarkers
0
VCL protein, human
0
cytolethal distending toxin
0
Vinculin
125361-02-6
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00064Références
Gastroenterology. 2005 Jul;129(1):98-104
pubmed: 16012939
Curr Treatm Opt Rheumatol. 2015 Mar 1;1(1):82-105
pubmed: 26005632
Aliment Pharmacol Ther. 2014 Feb;39(4):426-37
pubmed: 24387672
BMC Immunol. 2009 Sep 28;10:52
pubmed: 19785746
Dig Dis Sci. 2015 May;60(5):1195-205
pubmed: 25424202
Front Cell Infect Microbiol. 2016 Dec 05;6:168
pubmed: 27995094
Am J Gastroenterol. 2011 Jun;106(6):1089-98
pubmed: 21245834
Dig Dis Sci. 2017 Aug;62(8):1913-1922
pubmed: 28551709
Ann Clin Biochem. 1999 Nov;36 ( Pt 6):704-21
pubmed: 10586307
Gastroenterology. 2007 Mar;132(3):913-20
pubmed: 17383420
Clin Exp Gastroenterol. 2010;3:127-37
pubmed: 21694856
Am J Gastroenterol. 2000 Jan;95(1):67-71
pubmed: 10638561
Am J Gastroenterol. 2002 Sep;97(9):2290-9
pubmed: 12358247
Aliment Pharmacol Ther. 2014 Apr;39(8):767-79
pubmed: 24612362
Aliment Pharmacol Ther. 2009 Apr 15;29(8):834-42
pubmed: 19226291
Am J Gastroenterol. 2010 Aug;105(8):1835-42
pubmed: 20461070
Dig Dis Sci. 2017 Jun;62(6):1480-1485
pubmed: 28451914
Gastroenterology. 2014 May;146(6):1500-12
pubmed: 24583088
Gastroenterology. 2017 Apr;152(5):1042-1054.e1
pubmed: 28069350
Clin Gastroenterol Hepatol. 2007 Oct;5(10):1175-83
pubmed: 17686660
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Neurogastroenterol Motil. 2008 May;20 Suppl 1:121-9
pubmed: 18402649
J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:39-41
pubmed: 21443707
PLoS One. 2015 May 13;10(5):e0126438
pubmed: 25970536
Eur J Clin Invest. 2015 Dec;45(12):1350-9
pubmed: 26444549
Health Qual Life Outcomes. 2003 Aug 01;1:29
pubmed: 12914662
N Engl J Med. 2017 Jun 29;376(26):2566-2578
pubmed: 28657875
J Immunol Methods. 2009 Oct 31;350(1-2):125-32
pubmed: 19748508
Clin Chim Acta. 1986 Feb 28;155(1):69-76
pubmed: 3516456
J Neurogastroenterol Motil. 2010 Jan;16(1):30-4
pubmed: 20535323
Digestion. 2004;70(4):210-3
pubmed: 15627768
N Engl J Med. 2015 Nov 5;373(19):1853-63
pubmed: 26535514
Scand J Gastroenterol. 2005 Oct;40(10):1140-8
pubmed: 16265771